A detailed history of Bank Of America Corp transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Bank Of America Corp holds 264,622 shares of ATAI stock, worth $426,041. This represents 0.0% of its overall portfolio holdings.

Number of Shares
264,622
Previous 125,544 110.78%
Holding current value
$426,041
Previous $166,000 84.34%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.16 - $1.64 $161,330 - $228,087
139,078 Added 110.78%
264,622 $306,000
Q2 2024

Aug 14, 2024

BUY
$1.27 - $2.6 $54,613 - $111,807
43,003 Added 52.1%
125,544 $166,000
Q1 2024

May 15, 2024

SELL
$1.5 - $2.19 $714,144 - $1.04 Million
-476,096 Reduced 85.22%
82,541 $162,000
Q4 2023

Feb 14, 2024

SELL
$1.04 - $1.55 $2,987 - $4,453
-2,873 Reduced 0.51%
558,637 $787,000
Q2 2023

Aug 14, 2023

SELL
$1.44 - $2.19 $30,360 - $46,173
-21,084 Reduced 3.62%
561,510 $965,000
Q1 2023

May 12, 2023

BUY
$1.17 - $2.7 $573,331 - $1.32 Million
490,027 Added 529.38%
582,594 $1.05 Million
Q4 2022

Feb 10, 2023

SELL
$2.38 - $3.55 $16,093 - $24,005
-6,762 Reduced 6.81%
92,567 $246,000
Q3 2022

Nov 14, 2022

SELL
$3.14 - $4.87 $9,624 - $14,926
-3,065 Reduced 2.99%
99,329 $330,000
Q2 2022

Aug 12, 2022

BUY
$3.03 - $5.32 $30,339 - $53,269
10,013 Added 10.84%
102,394 $372,000
Q1 2022

May 16, 2022

SELL
$4.66 - $7.66 $63,077 - $103,685
-13,536 Reduced 12.78%
92,381 $470,000
Q4 2021

Feb 08, 2022

BUY
$6.82 - $17.8 $578,056 - $1.51 Million
84,759 Added 400.6%
105,917 $808,000
Q3 2021

Nov 15, 2021

BUY
$13.62 - $19.48 $286,128 - $409,235
21,008 Added 14005.33%
21,158 $313,000
Q2 2021

Sep 13, 2021

BUY
$16.94 - $19.89 $2,541 - $2,983
150 New
150 $3,000

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $267M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.